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Somatic mutations in exon 17 of the TEK gene in
vascular tumors and vascular malformations
Caisheng Ye, MD, PhD,a Lingxiao Pan, MD,a,b Yongbo Huang, MD,a Runyi Ye, PhD,a
Anjia Han, MD, PhD,c Songqi Li, MD, PhD,a Xiaoxi Li, MD, PhD,a and
Shenming Wang, MD, PhD,a Guangzhou City, Guangdong Province, China
Objective: As a common disease, the molecular etiology of noninherited vascular anomalies is still poorly understood.
Recently, somatic mutations in exon 17 of the endothelial cell tyrosine kinase receptor Tie-2 (encoded by TEK) were
identified in 49.1% of patients with common sporadic venous malformation, a subtype of vascular anomalies. We assessed
whether such a mutational region also had a role in the Chinese population or in other subtypes of noninherited vascular
anomalies (vascular tumors and vascular malformations).
Methods: Direct sequencing of polymerase chain reaction (PCR)-amplified DNA, extracted from 139 lesions in 129
individuals with noninherited vascular anomalies (vascular tumors or vascular malformations) and 60 control samples,
was used for detecting themutations in exon 17 of the TEK gene.Mutations were confirmed by allele-specific PCR. Clone
sequences were then used for the mutations identified for the first time. We also explored the associations between these
mutations and clinical characteristics (gender, onset age, number of lesions, severity, category, and recurrence of the
disease) in both vascular tumors and vascular malformations.
Results: Two somatic TEKmutations (Y897C, R915C) were identified in vascular tumors, and seven somatic TEKmutations
(Y897H, Y897C, L914F, R915C, S917I, R918C, R918H) were identified in vascular malformations. Among these
mutations, R918C (2,752C>T) andR918H (2,753G>A)were first identified in noninherited vascular anomalies. Somatic
TEKmutations were detected in lesions from 4 of 23 (17.4%) vascular tumors and 35 of 106 (33.0%) vascular malformations,
where most mutations were single substitutions in vascular tumors (100%) and vascular malformations (88.6%), while the
remainders were double substitutions. In addition to the reported venous malformation, such mutations were identified in
some other subtypes of vascular anomalies, including vascular tumors (infantile hemangioma, pyogenic granuloma, and
epithelioid hemangioma) and vascular malformations (capillary malformation, arteriovenous malformation, capillary lym-
phatic malformation, and capillary arteriovenous malformation). By contrast, these mutations were absent from the control
tissues or blood. However, mutations showed no association (P > .05) with clinical characteristics in vascular anomalies or
either of its two types (vascular tumors or vascular malformations).
Conclusions:Our study revealed that somatic mutations in exon 17 of the TEK gene were more common in noninherited
vascular anomalies than previously reported. Furthermore, such substitutions may shed new light on the molecular
etiology, diagnosis, and potential therapeutic targets of vascular anomalies. ( J Vasc Surg 2011;54:1760-8.)
Clinical Relevance:Vascular anomalies, divided into vascular tumors and vascularmalformations nowadays, is a common and
multidisciplinary involved disease that was originally termed “hemangiomas” or “vascular birthmarks.” Yet, the precise
molecular etiology is still poorly understood. In this hypothesis-generating study, we identified novel mutations, R918C and
R918H, of the TEK gene in noninherited vascular malformations. Additionally, we provided novel finding of somatic
mutations in exon 17 of the TEK gene in other seven subtypes of noninherited vascular anomalies besides reported venous
malformation. Our data highlight the broadening spectrum of somatic mutations in exon 17 of the TEK gene and are likely
to be of great value in terms of molecular etiology, diagnosis, and therapeutic targets of vascular anomalies in the future.
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1760Vascular anomalies is a common and multidisciplinary-
nvolved disease that was originally termed “hemangiomas”
r “vascular birthmarks.” On the basis of natural history,
linical manifestations, and histopathological features of
he disease, there are two popular classifications applied
n the world nowadays, the updated International Society
or the Study of Vascular Anomalies (ISSVA) classification
Table I)1 and the modified Hamburg classification.2 Ac-
ording to the modified Hamburg classification, congenital
ascular malformations are divided into arterial malforma-
ions, venous malformations, arteriovenous malformations,
ymphatic malformations, capillary malformations, and
ombined vascular malformations, based upon the pre-
ominant vascular structure in the malformation. This clas-
ification was further upheld and later modified by the
pdated ISSVA classification, which includes vascular tu-
ors together with vascular malformations.
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Volume 54, Number 6 Ye et al 1761Germ line mutations in greater than 10 genes, includ-
ing RASA1, CCM1/2/3, GLMN, TEK, VEGFR3,
FOXC2, SOX18, Endoglin, ACVRLK1, and MADH4,
have been identified in inherited vascular tumors and vas-
cular malformations.3-14 Despite this, the precise molecular
etiology of the more common noninherited vascular tu-
mors or vascular malformations is still poorly understood.
Limited studies have identified that somatic mutations in the
VEGFR2/3 gene are associated with infantile hemangi-
oma,15 and the TEK gene are associated with intramuscular
hemangiomas (capillary type and cavernous type)16 and com-
mon sporadic venous malformations.17 Limaye et al17 first
identified eight missense substitutions in exon 17 of the TEK
gene in 49.1% of patients with common sporadic venous
malformation, which was observed as the most common
subtype of vascular anomalies in our previous study.
Endothelial cell tyrosine kinase receptor Tie-2, en-
coded by TEK, is essential for both vessel remodeling
during angiogenesis and vascular integrity maintaining of
mature vessels.18 Tie-2 was thought to be expressed only in
endothelial cells; however, some studies19,20 revealed that
it could also be expressed in some monocytes. Since so-
matic mutations have been observed in both vascular tumor
and vascular malformations,15-17 given the limited under-
standing of mutations in exon 17 of the TEK gene in
noninherited vascular anomalies, we investigated whether
such a mutational region also had a role in the Chinese
population or in other subtypes of vascular anomalies other
than venous malformation.
METHODS
The current study complied with the Declaration of
Helsinki and was approved by the local Ethics Committee
with the informed consent from each study subject or his
Table I. Updated International Society for the Study of
Vascular Anomalies (ISSVA) classification of vascular
anomalies
Vascular tumors
Vascular
malformations
Infantile hemangiomas Slow-flow vascular
malformations:
Congenital hemangiomas CM; VM; LM.
Dermatologic acquired vascular tumors: Fast-flow vascular
malformations:
Pyogenic granuloma; Microvenular
hemangioma; AM; AVF; AVM.
Glomeruloid hemangioma, etc Complex-
combined
vascular
malformations:
Others: Kaposiform
hemangioendothelioma; Tufted angioma;
Lymphangioendotheliomatosis, etc
CVM; CLM;
LVM; CLVM;
AVM-LM;
CM-AVM.
A, Artery; AV, arteriovenous; C, capillary; F, fistula; L, lymphatic; M,
malformation; V, venous.guardian. oSelection of cases and controls. The current study
as conducted on 129 patients (Asian descent) with vascu-
ar tumors or vascular malformations during the period
etween September 1, 2007 and September 1, 2009. All
atients were from southeast China and were admitted to
he respective departments (vascular surgery, head and neck
urgery, pediatric surgery, dermatology, plastic surgery,
nd orthopedic surgery) of the First Affiliated Hospital of
un Yat-sen University. In all, 139 lesions from distinguish-
ng locations were obtained from the 129 patients, all of
hom were diagnosed with vascular anomalies by clinical
ppearances, biological behaviors of the lesions, investiga-
ions of imaging, and investigations of pathology. Of the
29 patients (male: female 1:1.08), aged from 23 days to
5 years, with an average of 16.8 years and a median of 12
ears (interquartile range, 22 years), 23 patients (17.8%)
ad vascular tumors and 106 patients (82.2%) had vascular
alformations that were comprised of 63 patients with
low-flow vascular malformations, 25 with fast-flow vascu-
ar malformations, and 18 with complex-combined vascular
alformations.
For patient selection, we applied the following exclu-
ion criteria: (1) out-patient; (2) vascular anomalies in-
olved intracranial tissues or viscera; (3) patient was diag-
osed with vascular anomalies preoperatively, but was
egative by the investigation of pathology; (4) inpatient
nderwent no resection at all.
The control samples consisted of: (1) blood samples
rom 20 patients that suffered from vascular anomalies; (2)
issues adjacent to the lesions (resected from the margin of
he postresection sample with a distance of at least 3 cm
way from the margin of lesion by naked eye, confirmed by
ematoxylin and eosin [HE] staining with no apparent
bnormal tissue) from 10 patients with vascular anomalies,
ncluding skins, subcutaneous tissues, and muscular tissues;
3) five tissue samples from varicose great saphenous veins,
ve tissue samples from abdominal aortic aneurysms, five
issue samples from femoral pseudoaneurysms, and 15 nor-
al vessel samples from mastectomy, cholecystectomy, or
mputation.
Detection ofmutations in exon 17 of the TEK gene.
enomic DNA were isolated from all tissues (frozen in liquid
itrogen and ground into powder) and peripheral blood by
sing the TIANamp Genomic DNA Kit (TIANGEN, Bei-
ing, China), followed by amplification of exon 17 of the TEK
ene by PCR. The primers used are shown in Table II (online
nly). All primers were synthesized by Invitrogen (Guang-
hou, China). The amplification was performed in a total of
0L, containing 1.5L template DNA, 1L sense primer,
L antisense primer, 20 L 2Master Mix (TIANGEN),
nd 16.5 L ddH2O. Cycling consisted of 94°C for 5 min-
tes, followed by 35 cycles of 94°C for 30 seconds, 55°C for
0 seconds, and 72°C for 60 seconds. The final extension was
erformed by incubation at 72°C for 5 minutes. PCR prod-
cts were sequenced by Invitrogen. Results were analyzed
sing DNASTAR Lasergene software (version 7.1.0, Madi-
on, Wisc) by comparing with the wild-type human sequence
btained from the National Center for Biotechnology Infor-
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December 20111762 Ye et alation (NCBI) database (http://www.ncbi.nlm.nih.gov/
ene/7010).
For each sample that contained mutations in exon 17 of
he TEK gene detected by direct sequencing of PCR, allele-
pecific PCR was used for confirmation. The primers and
nnealing temperatures used for allele-specific PCR are listed
n Table II (online only). The mismatched nucleotides were
esigned in the sense primers for the mutant type. In fact,
ucleotide mismatch in the primer at only the 3=-end was not
ometimes sufficient for distinguishing the wild- and mutant-
ype sequences.21,22 Thus, we designed additional mis-
atches at the second or the third nucleotide site from the
=-terminus. Both sense primers for wild- and mutant-type
ere applied to each sample in addition to the negative con-
rol group and the blank control group. The procedure for
llele-specific PCR was the same as described above with the
xception that reaction mixtures were half the volume and of
ifferent annealing temperatures according to the primers.
CR products were analyzed by 1.5% agarose gel electropho-
esis.
Finally, clone sequencing was applied to the samples
ith mutations (had not been reported in noninherited
ascular anomalies before) identified by both direct se-
uencing of PCR and allele-specific PCR. The entire
equence of exon 17 of the TEK gene and the pMD19-T
ector were ligated according to the manufacturer’s in-
tructions for the pMD19-T Simple Vector Kit (Takara,
alian, China). The ligation reaction was used to trans-
orm Escherichia coli DH5 (TIANGEN). Following
lue-white screening, white colonies were selected and
hen identified by colony PCR. The positive recombi-
ant plasmids were sequenced by Invitrogen. The results
ere analyzed by DNASTAR Lasergene software, as
escribed above.
Statistical analysis. Data were expressed as median
interquartile range) for non-normal distribution variables.
he associations between the mutations in exon 17 of the
EK gene and clinical characteristics (gender, onset age,
umber of lesions, severity, category, and recurrence of the
isease) were determined by using 2 test or Wilcoxon
ank-sum test. A value of P  .05 was considered statisti-
ally significant. All analyses were performed using the
tatistical Package for the Social Science (SPSS) version
3.0 (Chicago, Ill).
ESULTS
By direct sequencing of PCR and allele-specific PCR
roducts amplified from 41 lesions from 39 individuals
39/129, 30.2%) with noninherited vascular anomalies, we
ig 1. Detection of mutations in exon 17 of the TEK gene by direct
equencing and allele-specific polymerase chain reaction (PCR).A-G,
missense mutations in exon 17 of the TEK gene: Y897H; Y897C;
914F; R915C; S917I; R918C; R918H. MT, Mutant-type; WT,
ild-type. Arrows (left) show the positions of the mutations. Arrows
right) show the products obtained by allele-specific PCR.
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Volume 54, Number 6 Ye et al 1763Table III. Lesions with mutations in exon 17 of the TEK gene from patients with vascular anomalies (n  39)
Patient
Onset age
Location Size (cm)
Layer of lesion
Diagnosis Severity a Mutation
At
birth
After
birth C S M B & J
1  Left arm 6  Infantile
hemangioma
Moderate R915C
2  Right wrist 3   Infantile
hemangioma
Mild Y897C
3  Right elbow 2  Epithelioid
hemangioma
Mild Y897C
4  Right middle
finger
1   Pyogenic
granuloma
Moderate R915C
5  Right foot 3   VM Mild L914F
6  Right occiput 5   VM Mild R915C
7  Right wrist 3  VM Mild R915C
8  Right arm 
thorax Extensive
  VM Severe L914F
9  Left palm 4  VM Mild L914F
10  Left arm Extensive    VM Severe L914F
11  Right cheek 4  VM Mild R918C
12  Left sole 8   VM Moderate L914F
13  Left palm 5  VM Mild L914F
14  Left calf 13   VM Moderate L914F
15  Right thigh 14   VM Moderate R915C
16  Left shoulder 12  VM Moderate L914F
17  Right sole 4    VM Mild S917I
18  Right neck 2  VM Mild Y897C
19  Left knee 10    VM Moderate Y897C
20  Right thorax 3  VM Mild L914F
21  Left elbow 4  VM Moderate L914F
22  Right
forearm
10  VM Moderate L914F
23  Right thorax 8   VM Moderate L914F
24  Left forehead 4  VM Mild L914F
25  Right thigh 4  CM Moderate L914F
26  Right
forehead
2  CM Mild L914F
27  Left cheek 4  CLM Mild L914F
28  Left cheek 4   AVM Mild L914F
29  Left buttock 9   AVM Moderate L914F
30  Left thigh 8   AVM Moderate L914F
31  Right calf 4  AVM Moderate S917I
32  Right neck 3   AVM Mild S917I
33  Right calf 1  AVM Moderate L914F
34  Right neck 15  AVM Moderate R918H
35  Right neck 2   CM Mild R915C 
R918C
36  Left cheek 8  CM-AVM Moderate Y897C 
R918H
37  Left thigh 5  AVM Moderate Y897C 
R915C
38  Right arm 4   VM Moderate R915C
 Left ring
finger
2    VM R915C
39  Right middle
finger
1  AVM Moderate Y897H 
R918C
 Right wrist 4  AVM Y897H 
R918C
A, Artery; AV, arteriovenous; B & J, bone and joint; C, capillary; C, cutaneous tissue; F, fistula; L, lymphatic; M, malformation; M, muscular tissue; S,
subcutaneous tissue; V, venous.
aSeverity: mild (with no symptoms, without bone or joint involvement, the total size of lesion is5 cm); moderate (with mild symptoms, without bone or joint
involvement, the total size of lesion is 5-15 cm); severe (with severe symptoms such as functional compromise, disfigurement, or with bone or joint
involvement, or the total size of lesion is 15 cm).
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December 20111764 Ye et alidentified seven missense substitutions in exon 17 of the
TEK gene, including Y897H (2,689 T  C), Y897C
(2,690 AG), L914F (2,740 C T), R915C (2.743 C
T), S917I (2,750 G  T), R918C (2,752 C  T), and
R918H (2,753 G  A) (Fig 1, Table III). Among them,
two mutations (Y897C, R915C) were identified in vascular
tumors, and all these seven mutations were identified in
vascular malformations. Furthermore, both R918C and
R918H were identified in noninherited vascular anomalies
for the first time and were subsequently confirmed by clone
sequencing (Figs 2 and 3, online only). Previous re-
Fig 4. Hematoxylin and eosin (HE) staining for subtype
gene. A, infantile hemangioma (magnification 400);
magnification400); C, epithelioid hemangioma (left: m
lymphatic malformation (left: magnification 50; right:
fication 100; right: magnification 400); F, capillary a
venous malformation (magnification 100); H, capillarports17,23 revealed that the intracellular region of Tie-2 tonsists of 2 tyrosine kinase domains (TK) and a kinase
nsert domain (KID). In the current study, Y897, L914,
nd R915 are located at the first TK, while S917 and R918
re located at the KID. Table III summarizes clinical char-
cteristics of these 39 individuals with vascular anomalies.
f the 39 patient samples that had mutations, 35 (89.7%)
ad a single nucleotide mutation of one of the six missense
ubstitutions listed above except for Y897H, with corre-
ponding percentages of 57.1% (20/35, L914F), 17.1%
6/35, R915C), 11.4% (4/35, Y897C), 8.6% (3/35, S917I),
.9% (1/35, R918C), and 2.9% (1/35, R918H), respec-
ascular anomalies with mutations in exon 17 of the TEK
yogenic granuloma (left: magnification 100; right:
fication 200; right: magnification 400); D, capillary
ification 400); E, venous malformation (left: magni-
venous malformation (magnification 50); G, arterio-
formation (magnification 400).s of v
B, p
agni
magn
rterioively, while the remaining patient samples (4/39, 10.3%)
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Volume 54, Number 6 Ye et al 1765possessed double mutations (R915C  R918C, Y897C 
R918H, Y897C  R915C, and Y897H  R918C).
Among the 129 patients with vascular anomalies, muta-
tions were detected in lesions from 4 of 23 (17.4%) vascular
tumors and 35 of 106 (33.0%) vascular malformations,
where most mutations were single substitutions
in vascular tumors (100%) and vascular malformations
(88.6%). Furthermore, two patients with vascular malfor-
mations had evidence of multiple lesions, where one patient
had two lesions (right middle finger and right wrist) that
appeared after birth, while the other patient had a left ring
finger lesion that appeared at birth, but the right arm lesion
appeared 6 months after birth. Interestingly, the subtypes
and mutations of the two lesions were the same for each
patient.
The subtypes of noninherited vascular anomalies with
mutations in exon 17 of the TEK gene comprise: (1)
infantile hemangioma (n  2); (2) pyogenic granuloma
(n  1); (3) epithelioid hemangioma (n  1); (4) capillary
lymphatic malformation (n 1); (5) venous malformation
(n 21); (6) capillary arteriovenous malformation (n 1);
(7) arteriovenous malformation (n  9); (8) capillary mal-
formation (n  3). According to the HE staining (Fig 4),
vascular tumors (the first three subtypes listed above) dem-
onstrate hyperplasia of the endothelial cells and behave like
benign neoplasms. Vascular malformations (the remaining
five subtypes listed above), however, are lesions of morpho-
logic anomalies that consisted of different types of vessels,
Fig. 4.with quiescent endothelial cells. iWe found no mutation in exon 17 of the TEK gene in
ll the control samples, including seven blood samples and
our tissue samples adjacent to the lesions from patients
ith mutations in exon 17 of the TEK gene. All 129
atients with vascular anomalies observed in the study
enied family histories of vascular anomalies. We detected
oth wild- and mutant-type sequences in exon 17 of the
EK gene in the lesions from 39 patients with vascular
nomalies, but only wild-type sequences in the lesions from
ther patients (Fig 1). Taken together, all the mutations
etected in the study were somatic mutations.
We analyzed the effect of different clinical characteris-
ics on the mutations observed in exon 17 of the TEK gene
Table IV). No significant association (P  .05) was ob-
erved between these mutations and any of the clinical
haracteristics (gender, onset age, number of lesion, sever-
ty, category, or recurrence of the disease) in vascular
nomalies or either of its two types (vascular tumors or
ascular malformations).
ISCUSSION
Currently, it is believed that the multifactorial nature,
ncluding environmental and genetic factors, is associated
ith the pathogenesis of many diseases (peripheral arterial
isease, venous leg ulceration, breast cancer, and lung
ancer).24-28 However, despite being a common disease,
he etiology of noninherited vascular anomalies is still
oorly investigated. Recently, Limaye et al17 was the first to
tinued)dentify eight somatic mutations in exon 17 of the TEK
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December 20111766 Ye et algene in 49.1% of patients with common sporadic venous
malformation in Europe. In our hypothesis-generating
study, somatic mutations in exon 17 of the TEK gene were
also identified in Chinese patients with venous malforma-
tion. Furthermore, we identified novel mutations, R918C
(2,752 C  T) and R918H (2,753 G  A), of the TEK
gene in noninherited vascular malformations. The R918C
mutation has only been previously reported in familial
cutaneous and mucosal venous malformation (VMCM),29
and R918H has not been found in any disease to date.
Additionally, here we provided the novel finding of somatic
mutations in exon 17 of the TEK gene in seven subtypes of
noninherited vascular anomalies (infantile hemangioma,
pyogenic granuloma, epithelioid hemangioma, capillary
malformation, arteriovenous malformation, capillary lym-
phatic malformation, and capillary arteriovenous malfor-
mation). Although no association was observed between
the mutations and some clinical characteristics in vascular
anomalies or either of its two types (vascular tumors or
vascular malformations), our data highlight the broadening
spectrum of somatic mutations in exon 17 of the TEK gene.
Existing data revealed that the somatic mutation rates
of VEGFR2/3 gene in infantile hemangioma, exon 15 of
the TEK gene in intramuscular hemangiomas (capillary
type and cavernous type) and exon 17 of the TEK gene in
Table IV. Analysis of effect of different clinical characteris
vascular anomalies, vascular tumors, or vascular malformati
Variable
Vascular anomalies
(n1  129, n2  95)
MT
(n1  39,
n2  33)
WT
(n1  90,
n2  62) P
MT
(n1 
n2  4
Gender .957
Male 18 42 0
Female 21 48 4
Onset age .130
At birth 9 33 1
After birth 30 57 3
Number of
lesions
.845
Single 35 78 4
Multiple 4 12 0
Severitya .372
Mild 17 34 2
Moderate 20 46 2
Severe 2 10 0
Recurrenceb 1.000
Yes 2 4 0
No 31 58 4
Category .139
VT 4 19 —
VM 35 71 —
MT, Mutant-type; VM, vascular malformations; VT, vascular tumors; WT, w
n1 and n2 are expressed as numbers of patients available for the data of
respectively.
aSeverity criteria of the disease is the same as Table III.
bRecurrence criteria: the volume of mass has increased during the follow-u
investigations of imaging, or the mass appears again after complete resectiocommon sporadic venous malformation were found at L3.3% (2/15), 24.3% (9/37), and 49.1% (28/57),15-17
espectively. In the present study, mutations in exon 17 of
he TEK gene in vascular anomalies were found at a rate of
0.2% (39/129), with rates of 17.4% (4/23) and 33.0%
35/106) in vascular tumors and vascular malformations,
espectively. It is already well known that Tie-2 is essential
or both vessel remodeling and vascular integrity maintain-
ng.18 Therefore, TEK seems to be a promising target for
nvestigating such subtypes of vascular malformations. Al-
eit that vascular tumors and vascular malformations are
undamentally different from the root, somatic mutations
ave been found in both of them. In this way, it is also an
nteresting issue if somatic mutations in TEK gene have a
ole in both vascular tumors and vascular malformations.
The current study identified seven missense mutations
n exon 17 of the TEK gene, of which Y897H, Y897C,
914F, R915C, and S917I had already been reported in
ommon sporadic venous malformation by Limaye et al.17
he ratio of single/double mutations in vascular anomalies
n our study (89.7%/10.3%) was similar to that (85.7%/
4.3%) revealed by Limaye et al.17 At the same time, we
lso found that this ratio in vascular tumors (100%/0) was
igher than that in vascular malformations (88.6%/11.4%).
evertheless, we observed that 57.1% (20/35) of the single
utations in vascular anomalies involved L914F, whereas
n mutations in exon 17 of the TEK gene in patients with
cular tumors
22, n2  20)
Vascular malformations
(n1  107, n2  75)
WT
(n1  18,
n2  16) P
MT
(n1  35,
n2  29)
WT
(n1  72,
n2  46) P
.201 .587
9 18 33
9 17 39
.080 .808
15 8 18
3 27 54
1.000 .961
16 31 62
2 4 10
.541 .075
14 15 20
4 18 42
0 2 10
1.000 1.000
1 2 3
15 27 43
— —
— — —
— — —
pe.
er, onset age, number of lesions, severity, and category) and recurrence,
od (median: 25 months; interquartile range: 17 months) by naked eye ortics o
ons
Vas
(n1 
4,
)
ild-ty
(gendimaye et al17 found a 100% (24/24) association. This
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Volume 54, Number 6 Ye et al 1767variation is likely to be explained by the ethnic heterogene-
ity, different subtypes of vascular anomalies, and different
sample sizes. Moreover, the reason that the five mutations
(Y897H, L914F, R915C, S917I, and R918H) failed to
be identified in inherited vascular anomalies in previous
studies was probably because of the lethal effect on the
embryo in early development or the small sample sizes of
studies for inherited vascular anomalies. Aside from this,
the necessity for double missense mutations in a disease is
uncommon. Consistent with our data, Limaye et al17 indi-
cated that the somatic “second hit” might also play a
determining role in a few of the noninherited vascular
malformations. Furthermore, it is unknown why the sub-
types and the mutations from the two lesions (not tumors),
independent of location, were the same in each of the two
individuals in our study.
Surprisingly, in the current study, there was no discern-
able association between the mutations and any of the
clinical characteristics (gender, onset age, number of le-
sions, severity, category, or recurrence of the disease) in
vascular anomalies or either of its two types (vascular tu-
mors or vascular malformations). At the same time, there
was a weak, but not significant, association between the
mutations and the onset age in the vascular tumors group
(P  .080) or the severity in the vascular malformations
group (P  .075). To support our results, further studies
that are performed with larger sample size are needed.
Owing to the somatic, but not germline, mutations
identified in the current study, only a few cells from the
lesions contained mutations. Thus, we first directly se-
quenced PCR products for either known or unknown
mutations in exon 17 of the TEK gene, with its disadvan-
tages in separating the cell-based DNA amplification from
the mixed clones of the lesions. Allele-specific PCR, one of
the quickest methods for detecting mutations with high
sensitivity and specificity, can only identify known single
nucleotide changes because it is sensitive to the 3=-terminus
mismatches in the primers. Additionally, another limitation
of this technique is the adjustment of PCR amplification
conditions (including the optimization of the allele-specific
primers) for each point mutation.30 Furthermore, because
of the homogeneity of the DNA sequence, clone sequenc-
ing is especially suitable for somatic mutations, but the
complexity and relatively high expense limit its use in a
large number of samples with low mutant-type/wild-
type allele ratio. Altogether, here we present a feasible
and inexpensive mutation detection procedure for the
identification of somatic mutations with low mutant-type/
wild-type allele ratio: direct sequencing of PCR-amplified
DNA ¡ allele-specific PCR confirmation ¡ clone se-
quencing for the mutations without being reported before.
The main limitation of this study was that we only
investigated exon 17, but not other exons, of the TEK
gene. The present study also lacked samples from individ-
uals with inherited vascular anomalies, and the sample size
was small. Moreover, we still have no idea of the exact
molecular mechanism with these somatic mutations. Fi-ally, we wonder whether our findings will also be observed
n other races.
Wang et al16 and Limaye et al17 provided evidence
hat somatic mutations in TEK gene resulted in ligand-
ndependent hyperphosphorylation of Tie-2 in vitro. Saha-
inen et al31 and Fukuhara et al18 recently revealed the
ifferential function of Tie2 at cell–cell contacts and cell–
ubstratum contacts regulated by angiopoietin-1 (ligand
or Tie2). It showed that matrix-bound Ang1 induced cell
dhesion, motility, and Tie2 activation; in contrast, in contact-
ng cells, Ang1 induced the formation of Tie2-Tie2 transasso-
iated complex, leading to the inhibition of paracellular per-
eability. In the current study, somatic mutations in exon 17
f the TEK gene were observed in distinguishing disease
vascular tumors and vascular malformations). Taken to-
ether, it seems reasonable that such mutations may result in
ome potential changes in clinical phenotype, and we hypoth-
size that its distinguishing molecular effect in vascular tumors
r vascular malformations may be due to the spatial localiza-
ion of Tie2.
In conclusion, our study showed that somatic muta-
ions in exon 17 of the TEK gene were common in nonin-
erited vascular anomalies (vascular tumors and vascular
alformations). This is likely to be of great value in terms of
olecular etiology, diagnosis, and therapeutic targets of
ascular anomalies in the future.
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43, L914F; HM547044, R915C; HM547045, S917I; HM447043, R918C;
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amplification and analysis of mutations
Primer Sequence (5=–3=)
HM547040 sense CCTGGCCCCTTTTGAGTATTG
HM547040 antisense GACTTTAGAGGGAACTCCACA
HM547041 (M) CTCTCTTCCTTCCCTCCAGGA
HM547041 (W) CTCTCTTCCTTCCCTCCAGGC
HM547041 (C) GACTTTAGAGGGAACTCCACA
HM547042 (M) TCTCTTCCTTCCCTCCAGGCG
HM547042 (W) TCTCTTCCTTCCCTCCAGGCT
HM547042 (C) GACTTTAGAGGGAACTCCACA
HM547043 (M) CATGGAAACCTTCTGGACTGC
HM547043 (W) CATGGAAACCTTCTGGACTTC
HM547043 (C) GACTTTAGAGGGAACTCCACA
HM547044 (M) GGAAACCTTCTGGACTTCCTC
HM547044 (W) GGAAACCTTCTGGACTTCCTT
HM547044 (C) GACTTTAGAGGGAACTCCACA
HM547045 (M) CTGGACTTCCTTCGCAAGGT
HM547045 (W) CTGGACTTCCTTCGCAAGAG
HM547045 (C) TATCCAAAGCGAAGTCCTC
HM447043 (M) CTGGACTTCCTTCGCAAGAGA
HM447043 (W) CTGGACTTCCTTCGCAAGAGC
HM447043 (C) GACTTTAGAGGGAACTCCACA
HM447041 (M) TGGACTTCCTTCGCAAGAGCA
HM447041 (W) TGGACTTCCTTCGCAAGAGCC
HM447041 (C) GACTTTAGAGGGAACTCCACA
C, Antisense primer for both mutant- and wild-type alleles; M, sense primer
of the TEK gene; HM547041, Y897H; HM547042, Y897C; HM5470
HM447041, R918H.res for polymerase chain reaction (PCR) primers used for
Length of product (bp) Annealing temperature (°C)
C 438 55
G
C 266 63
T 266 63
G
G 265 57
A 265 57
G
T 215 57
C 215 57
G
T 212 55
C 212 55
G
175 55
175 55
T 203 57
C 203 57
G
A 202 65
G 202 65
G
for mutant-type allele; W, sense primer for wild-type allele. HM547040, exon 17
JOURNAL OF VASCULAR SURGERY
December 20111768.e2 Ye et alFig 2 (online only). Detection of R918C by clone sequencing of exon 17 of the TEK gene. A, Arrow shows a
substitution of cytosine to thymine at nucleotide 2752 in exon 17 of the TEK gene.B,Green bar shows the mismatched
nucleotide between the wild- and mutant-type.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 6 Ye et al 1768.e3Fig 3 (online only). Detection of R918H  Y897C by clone sequencing of exon 17 of the TEK gene. A, Arrows
show the substitutions of guanine to adenine at nucleotide 2753 and adenine to guanine at nucleotide 2,690 in exon
17 of the TEK gene. B, Green bars show mismatched nucleotides between the wild- and mutant-type in the same allele.
